Compounds such as clofop, fluticasone, etynodiol, phenol, cefoxitin, (-)-isoprenaline, ciglitazone, and clidinium bromide emerged as promising candidates that may influence VNN1 activity, opening avenues for novel therapeutic strategies against COVID-19. This evidence concerns the gene VNN1 and COVID-19.